Khondrion | Khondrion Announces First Patient Dosed in Phase II Study Targeting Debilitating Post-COVID Fatigue
SON4PEM trial advances development of sonlicromanol, aiming to address chronic fatigue in Post-COVID patients with post-exertional malaise
www.khondrion.com
SON4PEM trial advances development of sonlicromanol, aiming to address chronic fatigue in Post-COVID patients with post-exertional malaise
NIJMEGEN, The Netherlands – May 19, 2026 – Khondrion today announced that the first patient has been dosed in the Phase II SON4PEM study (NCT07298005), a key clinical milestone in the development of sonlicromanol beyond primary mitochondrial disease. Sonlicromanol is a proprietary small molecule therapy targeting fatigue associated with post-exertional malaise (PEM) in post-COVID syndrome.
The SON4PEM study is an investigator-initiated, randomized, double-blind, placebo-controlled Phase II trial conducted at Amsterdam University Medical Center and supported by ZonMw, The Netherlands Organisation for Health Research and Development (11080022420008).
====
Khondrion is a clinical stage biopharmaceutical company. The company’s lead asset, sonlicromanol, is a potentially first-in-class, brain-penetrant redox-modulator with anti-inflammatory properties, that targets key metabolic and inflammatory pathways, including pathways associated with prostaglandin E2 (PGE2) signaling. Sonlicromanol and other compounds from Khondrion’s proprietary library have the potential to be developed for a wide range of diseases and conditions with the aim of benefiting patients whose daily lives are severely impacted by mitochondrial impairment like primary mitochondrial diseases, the company’s main focus, and post-COVID. For more information visit www.khondrion.com.
